Lucid Diagnostics (LUCD) Shares Outstanding (Weighted Average) (2020 - 2026)

Lucid Diagnostics has reported Shares Outstanding (Weighted Average) for 7 years, with the latest figure at $140.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 103.64% year-over-year to $140.1 million; the trailing twelve-month figure through Mar 2026 stood at $140.1 million (up 103.64% YoY), and the FY2025 full-year result was $101.9 million, up 101.81% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $140.1 million, up from $101.9 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $140.1 million in Q1 2026, with the low at $35.1 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $58.9 million across 5 years, with a median of $45.0 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Weighted Average) jumped 153.41% — and 2024, when it climbed 9.87%.
• Lucid Diagnostics' Shares Outstanding (Weighted Average) stood at $36.2 million in 2022, then advanced by 15.44% to $41.8 million in 2023, then rose by 20.98% to $50.5 million in 2024, then surged by 101.81% to $101.9 million in 2025, then soared by 37.42% to $140.1 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $140.1 million (Q1 2026), $101.9 million (Q4 2025), and $108.2 million (Q3 2025), per Business Quant data.